Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Yahoo News
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based…
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirat…
-
General23 hours agoICAC investigating University of Wollongong as chancellor grilled at Inquiry
-
Noosa News12 hours agoBondi Beach terror attack: Police investigate threat against Westfield North Lakes in Queensland
-
Noosa News22 hours agoE-Scooter accident | Noosa Today
-
General20 hours agoCoalition ‘flabbergasted’ by Labor’s response to calls for royal commission into antisemitism